UBS Reduces Stake in Renalytix PLC
Renalytix AI Targets Profitability With Kidney Test Sales
Renalytix 1Q Loss/Shr 4c >RENX.LN
Press Release: Renalytix Plc Reports Financial Results for First Quarter of Fiscal Year 2025
Earnings Flash (RENX.L) RENALYTIX Reports Fiscal Q1 Revenue $522,000
10-Q: Q1 2025 Earnings Report
Renalytix Sees Major Stake Acquisition by Ruffer LLP
Renalytix AI Sees Shift in Voting Rights Control
Renalytix AI Schedules Key Shareholder Meeting
Renalytix Chairman Adjusts Stake in Company
Unicorn Asset Management Adjusts Stake in Renalytix
Renalytix AI Transitions to OTCQB for Cost Efficiency
Renalytix Appoints Executive Chairman
10-K: FY2024 Annual Report
Renalytix AI Reports Fiscal Year Financials
Renalytix AI Eyes Growth With £10M Fundraise and Restructuring
12 Health Care Stocks Moving In Monday's After-Market Session
Renalytix Reveals Total Share Capital and Voting Rights
Renalytix Receives Written Notification From Nasdaq On August 23, 2024 That Following The Presentation Of Its Operating And Financing Plan, The Co Has Been Granted An Extension Until October 25, 2024 To Regain Compliance With The Minimum Bid Price...
Renalytix AI Secures Nasdaq Listing Extension